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Abstract
Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis,
complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade,
non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and
could become the leading indication for liver transplantation. This overview briefly summarizes the most recent
data on the pathophysiology, diagnosis, and treatment of non-alcoholic fatty liver disease. Ongoing clinical trials
are focused on an array of disease mechanisms and reviewed here are how these treatments fit into the current
paradigm of substrate overload lipotoxic liver injury. Many of the approaches are directed at downstream events
such as inflammation, injury and fibrogenesis. Addressing more proximal processes such as dysfunctional satiety
mechanisms and inappropriately parsimonious energy dissipation are potential therapeutic opportunities that if
successfully understood and exploited would not only address fatty liver disease but also the other components
of the metabolic syndrome such as obesity, diabetes and dyslipidemia.
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Background
Non-alcoholic fatty liver disease (NAFLD) has become
increasingly common in parallel with the increasing
prevalence of obesity and other components of the
metabolic syndrome [1, 2] and it is projected to be the
leading indication for liver transplant within a decade
[3]. Briefly reviewed here are key studies presented in
the past two years that have shed light on the natural
history, diagnosis, and pathogenesis of non-alcoholic
steatohepatitis (NASH). Data from recent treatment
trials are reviewed and placed in the context of our
current understanding of the pathogenesis of NASH.
Natural history
NASH clearly progresses to cirrhosis with further de-
compensation leading to death or liver transplantation
in some individuals. Unfortunately we still do not have a
firm handle on how often this occurs based on longitu-
dinal studies, but the estimates based on cross-sectional
data are that 20-30% of adults living in affluent parts of
the world consuming a western diet have too much fat
in the liver (i.e., NAFLD), 2-5% have the subset of
NAFLD in which substantial liver injury is also present
(i.e., NASH) and 1-2% of all adults may be at risk for
progressing to NASH cirrhosis [4]. The projected annual
economic impact of this disease burden has been esti-
mated to be $103 billion in the US and €35 billion in the
UK, Germany, France, and Italy combined [5].
An ability to identify which patients are at greatest risk
for progressing to cirrhosis is essential for targeting
therapeutic interventions. Several studies have demon-
strated the importance of any degree of liver fibrosis in
the setting of NAFLD in predicting adverse outcomes.
The late Paul Angulo and his coauthors collected data
on 619 patients who had repeated liver biopsies (median
12.6 years apart) across multiple continents and reas-
sessed their biopsies by one expert pathologist [6]. They
demonstrated that fibrosis, hepatocyte ballooning and
portal inflammation but not steatosis correlated with
reduced survival. Loomba and colleagues also examined
outcomes and demonstrated that fibrosis progression
does occur in NAFL (NAFLD that is not NASH) but at
a slower rate than in NASH [7].
Earlier studies have shown that the presence of type 2
diabetes (T2DM), obesity, and older age are associated
with NASH and advanced fibrosis. A study by Wong
and colleagues in Hong Kong using vibration controlled
elastography (Fibroscan) identified increased liver stiff-
ness in 17.7% of their diabetics and liver biopsies in a
subset of their cohort identified NASH in 50% andCorrespondence: tetriba@slu.edu
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stage 3-4 fibrosis in 57% [8]. A European population
study similarly showed increased liver stiffness in 17.2%
of people with T2DM and NAFLD [9].
The observation that steatosis does not necessarily
correlate with outcomes may seem unintuitive as we
all tend to be impressed by substantial steatosis on
imaging or liver biopsy. But when considered in the
context of the pathophysiology of NASH (Fig. 1), the
transient storage of fatty acids as inert triglyceride,
the primary component of steatosis, may actually be
an adaptive or protective mechanism rather than part
of the pathophysiology and thus the magnitude of
this accumulation may not be not directly related to
liver injury. That being said, examination of the
NHANES dataset where liver histology is not known
demonstrated that severe steatosis by ultrasound or
an elevated alanine aminotransferase (ALT) are both
associated with increased liver related mortality [10].
How much of this risk is driven by undiagnosed
NASH is unknown.
NAFLD is also associated with hepatocellular carcin-
oma (HCC) [11]. HCC is commonly thought of as
occurring in the setting of cirrhosis or after decades of
chronic hepatitis B infection, and only occasionally in
the setting of chronic liver disease that has not yet pro-
gressed to cirrhosis. Importantly, a recent survey of US
veterans demonstrated that the preponderance of non-
cirrhotic HCC occurs in patients with NAFLD com-
pared to other causes of chronic liver disease [12]. This
observation suggests that we may need to rethink the
strategy of confining our current practice of performing
surveillance imaging only in cirrhotic NASH patients.
Fig. 1 Substrate overload lipotoxic injury (SOLLI) model of NASH pathogenesis. The primary metabolic substrates are the monosaccharides
glucose and fructose that are turned into fatty acids in the liver and fatty acids themselves that are delivered to the liver from adipose tissue.
From this perspective, the most proximal abnormalities in the pathogenesis of NASH are the supply of excess dietary carbohydrates and fatty
acids. The carbohydrates are derived from dietary intake and the fatty acids primary from adipose tissue, especially in the setting of insulin
resistance. Carbohydrates can be converted to fatty acids through the multi-enzymes process of de novo lipogenesis and the transcription factor
SREBP1c plays a dominant role in regulating the expression of these enzymes. Fatty acids in the liver can be oxidized by mitochondria or converted
back into triglyceride for export into the blood as VLDL. In the setting of carbohydrate and fatty acid substrate overload or impairment of the
pathways of fatty acid disposal, or perhaps most likely a combination of both arms, fatty acids may promote the generation of lipotoxic species
(e.g., diacylglycerols [DAGs], ceramides, lysophosphatidyl choline species [LPCs]) that mediate endoplasmic reticulum stress, mitochondrial dysfunction,
hepatocellular injury, inflammation, and apoptosis to produce the histological phenotype currently called NASH. These processes are then the stimuli
for fibrogenesis and possibly malignant transformation. Major modulators of the hepatocellular response to lipotoxic stress may include the gut
microbiome, a variety of cytokines, chemokines, and adipokines, free cholesterol, uric acid, free cholesterol and possibly periodic hypoxia caused
by obstructive sleep apnea (OSA). DNL, de novo lipogenesis; SREBP1c, sterol response element binding protein-1c; ACC, acetyl-Coenzyme A
carboxylase; FAS, fatty acid synthetase; SCD, stearoyl-Coenzyme A desaturase; CYP, cytochrome P450; PNPLA3, patatin like phospholipase
domain containing 3; VLDL, very low density lipoprotein; OSA, obstructive sleep apnea; HCC, hepatocellular carcinoma
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Diagnosis
Whereas NAFLD can be diagnosed by imaging studies
such as ultrasound, computed tomography (CT), or
magnetic resonance imaging (MRI), the presence of
NASH still requires a liver biopsy to identify the pres-
ence and location of its features such as inflammation,
hepatocyte ballooning, Mallory-Denk bodies, and early
fibrosis [13]. Because of the invasive nature and cost
of a biopsy, non-invasive means of detecting NASH
and various stages of liver fibrosis are sorely needed. A
study measuring specific serum metabolites identified
by mass spectrometry plus the presence of elevated
AST, fasting insulin and the PNPLA3 genotype was
found to be good at discerning NASH from NAFL in a
northern European cohort [14]. NASH is primarily a
disorder of fat metabolism and thus serum lipidomic
studies may offer the best opportunity to find specific
lipids in the blood that can distinguish NASH from
NAFL. Using a purely lipidomic approach, Loomba
and colleagues found specific oxidized arachidonic
acid species that robustly differentiated NASH from
NAFL in a small but extensively characterized cohort
in the US [15].
Non-invasively assessing fibrosis is the other major
unmet need in NASH diagnostics. A large number of al-
gorithms based on clinical data and imaging to assess fi-
brosis have been developed, but their major strength
tends to be in identifying advanced fibrosis with less util-
ity in earlier stages [16–19]. A newer technique takes a
different approach by looking at collagen turnover using
stable isotope labeling of new collagen [20], a technique
that may have promise in treatment trials where current
histological, serum and instrument based testing lack
sensitivity for small changes over short time periods.
Pathogenesis
Data from animal and human studies supports the con-
cept that the hepatocellular injury that characterizes
NASH is driven by an overload of primary metabolic
substrates (glucose, fructose and fatty acids) in the liver
resulting in diversion of fatty acids into pathways that
promote cellular injury and a dysfunctional response to
that injury (Fig. 1) [21–26]. Different aspects of these
pathways leading to NASH and the resulting fibrosis
likely vary among patients similar to the associated
complex diseases obesity and diabetes [27].
Treatment
Lifestyle modification with a focus on healthy eating,
weight loss when needed, and regular exercise remain
the cornerstone of therapy in adults [28–31] and chil-
dren [32]. When recommending healthy food choices, a
Mediterranean diet has been shown to be a good alter-
native to a western diet [13, 33]. Bariatric surgery can
be a good option in selected patients and a long term
follow up study has been shown to reverse NASH and
even substantial fibrosis in some [34, 35]. However, sur-
gery is possible in only a minority of patients and there
is clearly a need for pharmacological therapy [36, 37].
Prior clinical trial data suggest that pioglitazone or vita-
min E may be beneficial in non-diabetic NASH patients
[38] and the benefit of pioglitazone on reversing NASH
and improving fibrosis was recently confirmed in
diabetic patients [39]. More recent trial results are
reviewed below and the substrate overload lipotoxic
liver injury (SOLLI) model of NASH pathogenesis pro-
vides an organized approach to understanding these
multiple potential points of attack (Fig. 2).
There are no approved drugs for NASH but recent
trial data suggests that different approaches may be
beneficial in subgroups of patients with NASH. It
probably makes sense that no single therapy will re-
verse NASH in all patients since different patients
likely manifest the phenotype of NASH in response to
different genetic predispositions and environmental
exposures. In addition, a major challenge for taking
potential treatments through to approval by govern-
ment agencies has been identifying meaningful trial
endpoints. The field has moved forward due to the
combined efforts to address these issues by regulatory
agencies, industry, and academics [40].
The peroxisomal proliferator activated receptor
(PPAR) family of nuclear receptors sense the presence
of lipophilic molecules and regulate gene expression
accordingly. PPARα upregulates oxidative metabolism
in the liver and PPARδ does so predominately in
muscle. The PPARα/δ ligand elafibranor was evaluated
in the GOLDEN trial and appeared to resolve NASH
in the subgroup with more severe disease at baseline
who also received the highest dose [41]. Fibrosis im-
provement was also found in those whose NASH re-
solved. These findings have led to the initiation of an
ongoing phase 3 trial.
In a different approach to modulating metabolism, a
bile-acid derived ligand for the nuclear hormone recep-
tor FXR, obeticholic acid, was evaluated in the FLINT
trial. This drug was recently approved to treat primary
biliary cholangitis at a dose of 10 mg daily and in the
FLINT trial, subjects received a higher dose of 25 mg
daily for 72 weeks resulting in improvements in the
composite NAFLD activity score and fibrosis [42]. This
drug is also in a phase 3 trial.
Modulating the glucagon-like-1 (GLP-1) incretin
pathway has been a valuable adjunct in the treatment
of type 2 diabetes because of the diverse favorable ef-
fects of GLP-1 and its analogues in modulating me-
tabolism at multiple targets in the body. The GLP-1
analogue liraglutide is used to treat diabetes and was
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Fig. 2 The SOLLI model predicts targets of therapy. Shown are many of the agents that have been studied in recent clinical trials or are the
subject of ongoing trials. Healthy eating habits and bariatric surgery regulate the intake of metabolic substrates and thus their reduction is a
treatment approach targeting the most proximal events in the process. Pharmacologic manipulation of eating behaviors and satiety may also
be effective proximal interventions. Adipose tissue insulin resistance allows inappropriate lipolysis and release of fatty acids into the circulation
which can be taken up by the liver. Both fatty acids and glucose in the blood can be diverted to oxidative pathways (green arrows) in other
tissues and these pathways are thought to be augmented by exercise, PPARγ and PPARδ ligands, GLP-1 analogues, and other hypothetical
interventions under investigation. The synthesis of fatty acids in the liver, or de novo lipogenesis, can be down-regulated by decreasing the
regulatory transcription factor SREBP1c or by inhibiting specific enzymes in the DNL pathway. Fatty acids in the liver can be used in a large
number of metabolic pathways but for disposal, they are oxidized by mitochondria, peroxisomes, and certain cytochrome P450 isoforms
(CYPs) or reesterified to glycerol to form triglyceride. Pharmacologic promotion of triglyceride formation would increase lipoprotein secretion
into the blood as very low density lipoprotein (VLDL) and could thus increase the risk of cardiovascular disease–not a likely treatment approach
for NASH. Little is known about the lipotoxic species generated in NASH, but once these are better characterized, specifically inhibiting their
formation or accelerating their disposal could become effective treatment approaches. Many of the treatment approaches in current clinical
trials are focused on managing the consequences of lipotoxic injury by using anti-inflammatory agents, anti-apoptotic agents and anti-fibrotics.
(Red arrows indicate inhibitory approaches; green arrows indicate possible beneficial diversion of metabolic substrates)
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evaluated in patients with NASH in the LEAN trial in
the UK [43]. It was a small trial and barely met the
primary endpoint of resolution of NASH without
worsening of fibrosis (9/23 vs 8/22 placebo treated
patients, P 0.019). In a study of sitagliptin, a drug that
prevents breakdown of endogenous GLP-1, the drug
was not found to have any effect on liver histology or
ALT in patients with NASH [44]. Thus augmenting
the GLP-1 axis may have an adjunctive role in the
context of combination therapy but is unlikely to play
a major role as monotherapy.
Based on the hypothesis that the lobular inflammation
in NASH contributes to hepatocellular injury and
fibrogenesis [45], anti-inflammatory agents have been
investigated. A prior study of pentoxifylline was prom-
ising [46] but a trial of an effective anti-inflammatory
phosphodiesterase-4 inhibitor was negative [47]. More
recently, an antagonist of the chemokine 2 and che-
mokine 5 receptors (CCR2/5) called cenicriviroc has
been evaluated and the preliminary trial results sug-
gest improvements in fibrosis [48].
Even if treatments are found that reverse NASH,
some patients will continue to present with advanced
fibrosis or cirrhosis and thus effective antifibrotic
agents may always be needed [30]. Effective anti-NASH
drugs will likely have indirect antifibrotic effects by
eliminating the stimulus for fibrogenesis, but some
drugs have been designed to be directly antifibrotic
(e.g., the galectin-3 inhibitor MD-02) or increasing
extracellular matrix turnover (e.g. simtuzumab) and are
currently in clinical trials.
Future directions
Many of the current pharmacological approaches to
treating NASH are focused on relatively downstream
events of liver injury, inflammation and fibrogenesis.
It may be advantageous to manipulate the upstream
events leading to substrate overload such as central
nervous system control of satiety mechanisms and en-
ergy efficiency [49, 50]. Recent insights into the gen-
etic control of eating-related reward signaling [51] and
peripheral input to the CNS modulating the central
control of metabolism [52] raise the possibility of de-
veloping therapeutics not only for the liver but the
other components of the metabolic syndrome.
Conclusions
As we enter an era of increasing genomic, lipidomic
and metabolomic information, the future is bright for
improving our understanding of the pathogenesis of
NASH to the point where we can provide individual-
ized treatment. A challenge in the field now is to cor-
relate the emerging data with treatment responses to
attain this goal.
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